Limits...
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.

Finetti F, Terzuoli E, Giachetti A, Santi R, Villari D, Hanaka H, Radmark O, Ziche M, Donnini S - Endocr. Relat. Cancer (2015)

Bottom Line: There is evidence that an inflammatory microenvironment is associated with the development and progression of prostate cancer (PCa), although the determinants of intrinsic inflammation in PCa cells are not completely understood.They also show increased capacity to survive irrespective of anchorage condition, and overexpress EGFR compared to mPGES-1(KD) cells. mPGES-1 expression correlates with increased in vivo tumour growth and metastasis.Although EGFR inhibition reduces mPGES-1(SC) and mPGES-1(KD) cell xenograft tumour growth, we show that mPGES-1/PGE2 signalling sensitizes tumour cells to EGFR inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Department of Life SciencesUniversity of Siena, Via Aldo Moro 2, 53100 Siena, ItalyDepartment of Surgery and Translational MedicineUniversity of Florence, Largo Brambilla 3, 50134 Firenze, ItalyDepartment of Clinical and Experimental MedicineUniversity of Florence, Viale Pieraccini 18, 50139 Firenze, ItalyDepartment of Medical Biochemistry and BiophysicsKarolinska Institutet, SE-171 77 Stockholm, SwedenIstituto Toscano Tumori (ITT)Firenze, Italy.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical expression of mPGES-1, EGFR and α6-integrin in prostate cancer. (A) Representative images of mPGES-1 and EGFR expression in organ-confined (a and b) or advanced (c and d) prostate cancer. (B) Representative images of mPGES-1 and α6-integrin expression in advanced prostate cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4526795&req=5

fig1: Immunohistochemical expression of mPGES-1, EGFR and α6-integrin in prostate cancer. (A) Representative images of mPGES-1 and EGFR expression in organ-confined (a and b) or advanced (c and d) prostate cancer. (B) Representative images of mPGES-1 and α6-integrin expression in advanced prostate cancer.

Mentions: We investigated the correlation of mPGES-1 expression (immunohistochemistry) with staging and grading in a series of PCa cases. Overall, mPGES-1 expression was detected in 12/25 (48%) organ-confined PCa and in 21/27 (77.7%) advanced PCa (Fig. 1A). In human advanced PCa samples, both mPGES-1 and EGFR were co-expressed in a high percentage of cases (n=19/27, 70.3%; Fig. 1A). In the same group, α6-integrin, a stem cell marker (Marthick & Dickinson 2012, Hoogland et al. 2014), was negative or weakly stained (n=19/27; Fig. 1B). By contrast, only 7/25 (28%) of organ-confined tumours showed co-expression of mPGES-1 and EGFR (Fig. 1A, 70.3% vs 28%, see also panel a and b from an organ confined PCa sample vs c and d from an advanced PCa sample).


mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.

Finetti F, Terzuoli E, Giachetti A, Santi R, Villari D, Hanaka H, Radmark O, Ziche M, Donnini S - Endocr. Relat. Cancer (2015)

Immunohistochemical expression of mPGES-1, EGFR and α6-integrin in prostate cancer. (A) Representative images of mPGES-1 and EGFR expression in organ-confined (a and b) or advanced (c and d) prostate cancer. (B) Representative images of mPGES-1 and α6-integrin expression in advanced prostate cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4526795&req=5

fig1: Immunohistochemical expression of mPGES-1, EGFR and α6-integrin in prostate cancer. (A) Representative images of mPGES-1 and EGFR expression in organ-confined (a and b) or advanced (c and d) prostate cancer. (B) Representative images of mPGES-1 and α6-integrin expression in advanced prostate cancer.
Mentions: We investigated the correlation of mPGES-1 expression (immunohistochemistry) with staging and grading in a series of PCa cases. Overall, mPGES-1 expression was detected in 12/25 (48%) organ-confined PCa and in 21/27 (77.7%) advanced PCa (Fig. 1A). In human advanced PCa samples, both mPGES-1 and EGFR were co-expressed in a high percentage of cases (n=19/27, 70.3%; Fig. 1A). In the same group, α6-integrin, a stem cell marker (Marthick & Dickinson 2012, Hoogland et al. 2014), was negative or weakly stained (n=19/27; Fig. 1B). By contrast, only 7/25 (28%) of organ-confined tumours showed co-expression of mPGES-1 and EGFR (Fig. 1A, 70.3% vs 28%, see also panel a and b from an organ confined PCa sample vs c and d from an advanced PCa sample).

Bottom Line: There is evidence that an inflammatory microenvironment is associated with the development and progression of prostate cancer (PCa), although the determinants of intrinsic inflammation in PCa cells are not completely understood.They also show increased capacity to survive irrespective of anchorage condition, and overexpress EGFR compared to mPGES-1(KD) cells. mPGES-1 expression correlates with increased in vivo tumour growth and metastasis.Although EGFR inhibition reduces mPGES-1(SC) and mPGES-1(KD) cell xenograft tumour growth, we show that mPGES-1/PGE2 signalling sensitizes tumour cells to EGFR inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Department of Life SciencesUniversity of Siena, Via Aldo Moro 2, 53100 Siena, ItalyDepartment of Surgery and Translational MedicineUniversity of Florence, Largo Brambilla 3, 50134 Firenze, ItalyDepartment of Clinical and Experimental MedicineUniversity of Florence, Viale Pieraccini 18, 50139 Firenze, ItalyDepartment of Medical Biochemistry and BiophysicsKarolinska Institutet, SE-171 77 Stockholm, SwedenIstituto Toscano Tumori (ITT)Firenze, Italy.

No MeSH data available.


Related in: MedlinePlus